“A Quick Guide to Clinical Trials” Book Review
A brief review of “A Quick Guide to Clinical Trials,” edited by Dr. Madhu Davies and Dr. Faiz Kermain.
May 14, 2008-“A Quick Guide to Clinical Trials,” edited by Dr. Madhu Davies and Dr. Faiz Kermain, and offered by BioPlan Associates, truly lives up to its title. While it could serve as a textbook for a primer class on the clinical trials industry, the quick read would be suitable for anyone wishing to learn more about clinical trials-including people outside or inside the industry. If you are in data management, for example, and want to learn more about ethics in clinical research-or vise versa-this would be a useful resource. The book consists of 14 chapters dedicated to a different segment of the clinical trials process, each written by an industry expert. The information is up-to-date and offers personal, yet professional, insights into the current issues applicable to that segment.
For more information or to purchase, contact: www.bioplanassociates.com/quickGuides.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
